Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 287Specimen Handling 285pembrolizumab 258Cyclophosphamide 237Radiotherapy 233Nivolumab 187Cisplatin 174Biopsy 170Carboplatin 155Radiosurgery 142fludarabine 131Blood Specimen Collection 130Surveys and Questionnaires 120Gemcitabine 120Paclitaxel 115venetoclax 114Standard of Care 112Dexamethasone 105Bevacizumab 98Radiation 97Rituximab 92Oxaliplatin 89Cytarabine 88Capecitabine 88Drug Therapy 86Ipilimumab 85Doxorubicin 83durvalumab 81atezolizumab 76fludarabine phosphate 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pegloticase × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡